<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Penney J</submitter><funding>NIA NIH HHS</funding><pagination>452-469</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10904109</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>72(2)</volume><pubmed_abstract>Genetic findings have highlighted key roles for microglia in the pathology of neurodegenerative conditions such as Alzheimer's disease (AD). A number of mutations in the microglial protein triggering receptor expressed on myeloid cells 2 (TREM2) have been associated with increased risk for developing AD, most notably the R47H/+ substitution. We employed gene editing and stem cell models to gain insight into the effects of the TREM2 R47H/+ mutation on human-induced pluripotent stem cell-derived microglia. We found transcriptional changes affecting numerous cellular processes, with R47H/+ cells exhibiting a proinflammatory gene expression signature. TREM2 R47H/+ also caused impairments in microglial movement and the uptake of multiple substrates, as well as rendering microglia hyperresponsive to inflammatory stimuli. We developed an in vitro laser-induced injury model in neuron-microglia cocultures, finding an impaired injury response by TREM2 R47H/+ microglia. Furthermore, mouse brains transplanted with TREM2 R47H/+ microglia exhibited reduced synaptic density, with upregulation of multiple complement cascade components in TREM2 R47H/+ microglia suggesting inappropriate synaptic pruning as one potential mechanism. These findings identify a number of potentially detrimental effects of the TREM2 R47H/+ mutation on microglial gene expression and function likely to underlie its association with AD.</pubmed_abstract><journal>Glia</journal><pubmed_title>iPSC-derived microglia carrying the TREM2 R47H/+ mutation are proinflammatory and promote synapse loss.</pubmed_title><pmcid>PMC10904109</pmcid><funding_grant_id>RF1 AG054321</funding_grant_id><funding_grant_id>RF1 AG062377</funding_grant_id><pubmed_authors>Loon A</pubmed_authors><pubmed_authors>Ralvenius WT</pubmed_authors><pubmed_authors>Penney J</pubmed_authors><pubmed_authors>Dileep V</pubmed_authors><pubmed_authors>Cerit O</pubmed_authors><pubmed_authors>Pao PC</pubmed_authors><pubmed_authors>Tsai LH</pubmed_authors><pubmed_authors>Milo B</pubmed_authors><pubmed_authors>Woolf H</pubmed_authors></additional><is_claimable>false</is_claimable><name>iPSC-derived microglia carrying the TREM2 R47H/+ mutation are proinflammatory and promote synapse loss.</name><description>Genetic findings have highlighted key roles for microglia in the pathology of neurodegenerative conditions such as Alzheimer's disease (AD). A number of mutations in the microglial protein triggering receptor expressed on myeloid cells 2 (TREM2) have been associated with increased risk for developing AD, most notably the R47H/+ substitution. We employed gene editing and stem cell models to gain insight into the effects of the TREM2 R47H/+ mutation on human-induced pluripotent stem cell-derived microglia. We found transcriptional changes affecting numerous cellular processes, with R47H/+ cells exhibiting a proinflammatory gene expression signature. TREM2 R47H/+ also caused impairments in microglial movement and the uptake of multiple substrates, as well as rendering microglia hyperresponsive to inflammatory stimuli. We developed an in vitro laser-induced injury model in neuron-microglia cocultures, finding an impaired injury response by TREM2 R47H/+ microglia. Furthermore, mouse brains transplanted with TREM2 R47H/+ microglia exhibited reduced synaptic density, with upregulation of multiple complement cascade components in TREM2 R47H/+ microglia suggesting inappropriate synaptic pruning as one potential mechanism. These findings identify a number of potentially detrimental effects of the TREM2 R47H/+ mutation on microglial gene expression and function likely to underlie its association with AD.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-06-02T11:59:08.793Z</modification><creation>2025-04-03T23:22:34.803Z</creation></dates><accession>S-EPMC10904109</accession><cross_references><pubmed>37969043</pubmed><doi>10.1002/glia.24485</doi></cross_references></HashMap>